ArticleBMC cardiovascular disorders2025
Association of atherogenic index of plasma with cardiovascular disease mortality in patients with type 2 diabetes mellitus and diabetic kidney disease: a cross-sectional study.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Effectiveness of plasma atherogenic index as a predictor of cardiovascular risk in patients with metabolic syndrome and related cardiometabolic conditions: a systematic review.Cardiovascular endocrinology & metabolism · 2026Review
- Atherogenic Index of Plasma is Independently Associated With Microalbuminuria in Type 2 Diabetes: A Retrospective Cross-Sectional Study.Journal of diabetes research · 2026Article
- Development and validation of a prediction model for microvascular complications of type 2 diabetes based on inflammation-metabolism composite indicators.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesType 2 diabetes mellitus (T2DM) and diabetic kidney disease (DKD) may exacerbate atherosclerosis through mechanisms such as chronic inflammation, oxidative stress, and lipid redistribution. This study aims to investigate the relationship between atherogenic index of plasma (AIP) and cardiovascular disease (CVD) mortality in patients with T2DM and DKD.
methodsCOX regression models and restricted cubic spline (RCS) curves were utilized to analyze the survival outcomes and non-linear associations among patients with T2DM and DKD. Threshold effects were observed in both global and inflection point models, confirming the predictive value of AIP for participants. Subgroup analysis further investigated the interaction of other variables within the AIP index on T2DM and patients with DKD with CVD mortality.
resultsA total of 5,108 patients diagnosed with T2DM, along with 1,598 patients suffering from DKD, were included in this study. In patients with DKD, the AIP index has a "U"-shaped association with CVD mortality. The hazard ratio (HR) and 95% confidence interval of the third quartile of CVD mortality in patients with DKD is Model3: 0.76 (0.61-0.96) (P < 0.023). The inflection point of the threshold effect analysis is 0.14. When AIP is less than 0.14, the effect size and 95% confidence interval of CVD mortality risk in patients with DKD is 0.62 (0.40-0.96) (P < 0.033). When AIP is greater than or equal to 0.14, the effect size and 95% confidence interval of CVD mortality risk in patients with DKD is 1.68 (1.15-2.45) (P < 0.008).
conclusionsThe relationship between AIP and CVD mortality in patients with DKD exhibits a "U" shaped curve, with a turning point value of 0.14. When AIP is below 0.14, the risk significantly decreases (HR = 0.62); conversely, when AIP is equal to or exceeds 0.14, the risk markedly increases (HR = 1.68).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.